What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Breast cancer, Internal medicine, Oncology, Chemotherapy and Cancer.
His Breast cancer research integrates issues from Gynecology, Adjuvant therapy and Hazard ratio.
His Oncology research includes elements of Taxane, Phases of clinical research, Regimen, Letrozole and Clinical endpoint.
John Crown has included themes like Gastroenterology and Radiation therapy in his Chemotherapy study.
His research integrates issues of Cell culture, Cancer research, Immunology and Bioinformatics in his study of Cancer.
His Trastuzumab study combines topics in areas such as Protein kinase B and Monoclonal.
His most cited work include:
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer (2615 citations)
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer (1644 citations)
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study (1066 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer research and Cancer.
His Internal medicine study frequently links to related topics such as Surgery.
John Crown has researched Breast cancer in several fields, including Targeted therapy and Immunology.
His Adjuvant study in the realm of Oncology connects with subjects such as In patient.
His Cancer research research is multidisciplinary, incorporating elements of Cell culture, Cell growth, Tyrosine kinase, SKBR3 and Gene.
The various areas that John Crown examines in his Chemotherapy study include Gastroenterology, Disease and Anthracycline.
He most often published in these fields:
- Internal medicine (61.37%)
- Breast cancer (56.34%)
- Oncology (52.92%)
What were the highlights of his more recent work (between 2016-2021)?
- Breast cancer (56.34%)
- Internal medicine (61.37%)
- Oncology (52.92%)
In recent papers he was focusing on the following fields of study:
John Crown spends much of his time researching Breast cancer, Internal medicine, Oncology, Cancer research and Cancer.
His studies deal with areas such as Targeted therapy and Disease as well as Breast cancer.
His study in Chemotherapy, Stage, Clinical trial, Metastatic breast cancer and Hazard ratio falls under the purview of Internal medicine.
The concepts of his Oncology study are interwoven with issues in Immune system and Docetaxel.
His Cancer research research is multidisciplinary, incorporating perspectives in Cell culture, Neratinib, Tyrosine kinase, Mutant and Lapatinib.
His work carried out in the field of Cancer brings together such families of science as Mutation, Serous fluid, Myeloid leukemia and Calcitriol receptor.
Between 2016 and 2021, his most popular works were:
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (502 citations)
- Mutant p53 as a target for cancer treatment. (104 citations)
- Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. (60 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Breast cancer, Cancer research, Internal medicine, Oncology and Clinical trial are his primary areas of study.
Trastuzumab is the focus of his Breast cancer research.
His Cancer research research includes themes of Cancer, Mutant, Lapatinib, Estrogen receptor and Triple-negative breast cancer.
His works in Randomized controlled trial, Letrozole and Phases of clinical research are all subjects of inquiry into Internal medicine.
His Oncology study combines topics from a wide range of disciplines, such as Neoadjuvant therapy, Trastuzumab emtansine and Chemotherapy, Docetaxel.
His Clinical trial study also includes fields such as
- Hazard ratio which is related to area like Clinical endpoint, Axilla and Mastectomy,
- Adverse effect which is related to area like Surgery, Lung and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
